Research, multi-centre trial | Treatment of CFS and Fibromyalgia with D-ribose | 4 July 2012

From The Open Pain Journal, 4 July 2012

Treatment of Chronic Fatigue Syndrome and Fibromyalgia with D-Ribose – An Open-label, Multicenter Study.

Jacob Teitelbaum, Janelle Jandrain and Ryan McGrew Pp 32-37
(Academic affiliations not stated)


OBJECTIVES: Chronic Fatigue Syndrome and Fibromyalgia (CFS/FMS) are debilitating syndromes affecting ~2- 4% of the population. Although they are heterogeneous conditions associated with many triggers, they appear to have the common pathology of being associated with impaired energy metabolism.

As D-ribose has been shown to increase cellular energy synthesis, and was shown to significantly improve clinical outcomes in CFS/FMS in an earlier study, we hypothesized that giving D-ribose would improve function in CFS/FMS patients.

DESIGN, LOCATION AND SUBJECTS: An open-label, unblinded study in which 53 US clinics enrolled 257 patients who had been given a diagnosis of CFS/FMS by a health practitioner.

INTERVENTIONS: All subjects were given D-ribose (Corvalen™), a naturally occurring pentose carbohydrate, 5-g TID for 3 weeks.

OUTCOME MEASURES: All patients were assessed at baseline (1 week before treatment), and after 1,2, & 3 weeks using a Visual Analog Scale(1-7 points) rating energy, sleep, cognitive function, pain and overall well being.

RESULTS: 203 patients completed the 3 week treatment trial. D-ribose treatment led to both statistically(p<.0001) and clinically highly important average improvements in all categories: • 61.3 % increase in energy • 37% increase in overall well being • 29.3% improvement in sleep • 30% improvement in mental clarity • 15.6% decrease in pain Improvement began in the first week of treatment, and continued to increase at the end of the 3 weeks of treatment. The D-ribose was well tolerated. CONCLUSIONS: In this multicenter study, D-ribose resulted in markedly improved energy levels, sleep, mental clarity, pain relief, and well being in patients suffering from fibromyalgia and chronic fatigue syndrome. NCT01108549